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Background: Leukocyte migration across the blood barrier and into tissues represents a key process in the pathogenesis of inﬂammatory bowel
diseases. The urokinase receptor (urokinase-type plasminogen activator receptor) is a master regulator of leukocyte recruitment. We recently found that
cyclization of the urokinase-type plasminogen activator receptor–derived peptide Ser-Arg-Ser-Arg-Tyr [SRSRY] inhibits transendothelial migration of
monocytes. Now, we have explored the effects of [SRSRY] administration during experimental colitis.
Methods: The effects of [SRSRY] on cytokine proﬁle, cytoskeletal organization, and cell migration were investigated using phorbol-12-myristate
acetate–differentiated THP-1 cells exposed to polarizing stimuli. In vivo, [SRSRY] was intraperitoneally administered during dextran sodium sulfate– or
2,4,6-trinitrobenzene sulfonic acid–induced colitis in wild-type or urokinase-type plasminogen activator receptor knockout mice. Levels of pro-
inﬂammatory cytokines and inﬂammatory monocytes in mucosal inﬁltrates were assessed by enzyme-linked immunosorbent assay and ﬂow cytometry,
respectively.
Results: [SRSRY] prevents M0 to M1 transition and migration of M1 polarized macrophages. In vivo, [SRSRY] reduces intestinal inﬂammation
diminishing body weight loss and disease activity index. These beneﬁcial effects are accompanied by a reduction of interleukin 1b, interleukin 6, and
tumor necrosis factor a, an increase of interleukin 10, and an abridged recruitment of inﬂammatory monocytes to the inﬂamed tissue.
Conclusions: Altogether, these ﬁndings indicate that [SRSRY] may be considered as a new drug useful for the pharmacological treatment of chronic
inﬂammatory diseases, such as inﬂammatory bowel diseases.
(Inﬂamm Bowel Dis 2016;0:1–12)
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I nﬂammatory bowel diseases (IBD), including Crohn’s diseaseand ulcerative colitis, refer to chronic inﬂammatory disorders
that affect the gastrointestinal tract.1 Even if their etiology is still
not completely understood, it has been clariﬁed that IBD have
genetic and environmental components and seem to be immuno-
logically mediated in part by enteric microbiota.1,2 Indeed, intes-
tinal immune cells, such as dendritic cells and macrophages,
interact with an abnormal antigen loads, and their ability in sus-
taining microbial tolerance is lost during IBD.3 Furthermore, the
chronicity of the inﬂammation is prolonged and maintained by an
aberrant recruitment and activation of intestinal leukocytes to the
inﬂamed tissue.1,2
The urokinase-type plasminogen activator receptor (uPAR)
regulates the activation and mobilization of leukocytes, being
expressed by a wide variety of hematologic cells, including
monocytes and macrophages.4,5
We recently proved that uPAR is able to control macro-
phage phagocytosis during experimental colitis.6 Indeed, we
observed that genetic deletion of uPAR augmented mouse sus-
ceptibility to experimental colitis models.6 We and others have
documented that uPAR is able to control cell migration through
the assembly in composite regulatory units with transmembrane
receptors, including formyl peptide receptors (FPRs) and the vi-
tronectin receptor which, in turn, signal across the membranes.7
Ligand-activated uPAR exposes on cell surface the minimal
active 88Ser-Arg-Ser-Arg-Tyr92 sequence, able to trigger cell
migration and angiogenesis in vitro and in vivo, even in the form
of synthetic linear peptide Ser-Arg-Ser-Arg-Tyr (SRSRY).8–10
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Mechanistically, uPAR88–92 sequence interacts with the FPR
types 1 and 2, henceforth inducing cell migration of several cell
lines including monocytes and macrophages.8,9,11
We have recently documented that the cyclization of the
Ser-Arg-Ser-Arg-Tyr peptide generates the peptide [SRSRY]
exerting opposite effect on cell migration, as compared with its
linear form. Unlike the linear peptide SRSRY, [SRSRY] blocks
FPR1-mediated signaling by interfering with both internalization
of FPR1 and ligand uptake. [SRSRY] inhibits monocyte locomo-
tion with IC50 value of 0.01 nM and displays a long-time resis-
tance to enzymatic digestion in serum. Notably, at 10 nM
concentration, [SRSRY] prevents transendothelial migration of
monocytes and causes a marked inhibition of their cytoskeletal
reorganization occurring during locomotion.12
In the present study, we explored the effects elicited by the
administration of [SRSRY] in 2 experimental models of colitis,
characterizing the recruitment and the activation of monocytes
and macrophages into the inﬂamed intestine. Herein, we show
that [SRSRY] possesses anti-inﬂammatory properties, reducing
the inﬁltration of inﬂammatory monocytes and inﬂuencing
macrophage polarization.
MATERIALS AND METHODS
Ethics Statement
Animal experiments adhered to the requirements of the
Commission Directive 86/609/EEC and to the Italian legislation
(Decreto Legislativo 116; January 27, 1992). The studies were
approved by the Animal Care and Use Committee (authorization
no. 192/2012-B; Istituto Clinico Humanitas, Milan, Italy).
Peptide Synthesis and Puriﬁcation
Cyclic peptides [Ser-Arg-Ser-Arg-Tyr] ([SRSRY]) and [Arg-
Ser-Ser-Tyr-Arg] ([RSSYR]) were synthesized by Fmoc chemistry
solid-phase approach and puriﬁed by reverse-phase HPLC, as
previously described.12
Generation of M1 Polarized Macrophages
Human monocyte leukemia THP-1 cell line (American Type
Culture Collection) was cultured in RPMI 1640 medium, supple-
mented with 10% heat-inactivated fetal bovine serum, penicillin (100
mg/mL), and streptomycin (100 U/mL). THP-1 monocytes were
differentiated with 160 nM phorbol-12-myristate acetate (PMA;
Sigma-Aldrich, Milan, Italy) for 2 days. M1 macrophage polariza-
tion was achieved adding 100 ng/mL lipopolysaccharide + 20 ng/mL
interferon (IFN) g (both from Sigma-Aldrich) to PMA-differentiated
THP-1 cells for additional 2 days, as described.13 In parallel experi-
ments, M1 polarization occurred in the presence of 10 nM [SRSRY].
Cytokine Array
To conﬁrm the polarization of macrophages into the M1
subtype after stimulation, conditioned media were collected and
centrifuged at 1000 rpm for 5 minutes to remove cell debris. The
relative levels of cytokines were analyzed using the dot blot
Human Cytokine Array Kit panel A (no. ARY005; R&D Sys-
tems, Milan, Italy), according to the manufacturer’s instructions.
Brieﬂy, 500 mL of supernatant was applied on each membrane,
and the signals were detected using streptavidin–horseradish per-
oxidase and chemoluminescent detection reagents. The pixel den-
sity of each spot was measured using NIH Image J 2.0 software.
The intensity of positive control spots was used to normalize
results between the membranes. The intensity for each spot was
then averaged over the duplicate spots.
Fluorescence Microscopy
To analyze FPR1 expression, M1 polarized THP-1 cells
were incubated with 2 mg/mL rabbit anti-FPR1 antibody (Santa
Cruz Biotechnology, Milan, Italy) for 2 hours at 238C and then
with 1:800 goat Alexa Fluor 488 anti-rabbit immunoglobulin G
(Molecular Probes, Milan, Italy) at 238C for 45 minutes. Nuclear
staining was performed with 4-6-diamidino-2-phenylindole dye. To
analyze the effect of [SRSRY] on FPR1 internalization, cells were
incubated with the indicated unlabeled peptides for 30 minutes at
378C and then exposed to 10 nM N-formyl-Nle-Leu-Phe-Nle-Tyr-
Lys-ﬂuorescein (FITC-fMLF; Molecular Probes) for 30 minutes at
378C, as described.14 To analyze cytoskeletal organization, cells
were ﬁxed and permeabilized with 2.5% formaldehyde–0.1% Tri-
ton X-100 in phosphate-buffered saline for 10 minutes at 48C,
washed in phosphate-buffered saline, and then incubated with 0.1
mg/mL rhodamine-conjugated phalloidin (Invitrogen, Milan, Italy)
at 238C for 45 minutes. In all cases, coverslips were mounted using
20% (wt/vol) mowiol and analyzed by a ﬂuorescence-inverted
microscope connected to a video camera or by the confocal 510
META LSM microscope (Carl Zeiss, Milan, Italy).
DUNN Chamber Assay
M1 polarized THP-1 cells were seeded on 20 · 20 mm
coverslips for 24 hours. Before inverting the coverslip on top of
a double-concentric DUNN chamber, cells on the coverslip cov-
ering the outer chamber were carefully scraped away, as previ-
ously described.15 A gradient of a chemoattractant was created by
placing serum-free medium in the inner chamber and 10 nM
fMLF with or without 10 nM [SRSRY] or 10 nM [RSSYR] in
the outer chamber. The ring separating the inner and outer cham-
bers permits slow diffusion between the chambers. For control
experiments, both wells were ﬁlled with serum-free medium.
After 6 hours of incubation at 378C with 5% CO2, the coverslip
was removed from the chamber and the cytoskeleton was visual-
ized by staining with rhodamine-conjugated phalloidin. A total of
100 cells per sample, which translocated to the area corresponding
to the ring separating the inner and outer chambers, were counted,
and their cytoskeletal organization was examined with a ﬂuores-
cence-inverted microscope connected to the video camera.
Cell Viability
The viability of LPS/IFNg-stimulated THP-1 macrophages
was investigated using the CellTiter 96 AQueous Cell Proliferation
Assay Kit (Promega, Milan, Italy), according to the manufacturer’s
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instructions. PMA-differentiated THP-1 cells (2 · 104 cells per
well) were seeded in 96-well tissue culture plates, exposed to
polarizing stimuli for 48 hours, and then incubated with 10 mM
[SRSRY], 10 mM [RSSYR], or diluents. Medium with or without
peptides was replaced every 24 hours. After 24, 48, and 72 hours,
suspended cells were removed and the adherent cells stained with
tetrazolium/formazan for 3 hours at 378C. The absorbance was
detected at 490 nm using a microplate reader (Bio-Rad Laborato-
ries, Segrate [MI], Italy).
Mice
Wild-type C57BL6 mice were purchased by Charles River
Laboratories (Calco, Lecco, Italy). uPAR knockout (KO) mice16
were kindly provided by Nicolai Sidenius (IFOM-IEO, Milan,
Italy) and maintained on C57BL6/N genetic background. Animals
were kept under speciﬁc pathogen-free conditions. Six-to 10-
week-old, age-matched, and sex-matched wild-type (WT) and
KO littermates were used for all experiments. Typically, 4 to 6
mice were used for each group of treatment, and the experiment
was repeated at least 3 times.
Mouse Models of Colitis and
Colitis Evaluation
Colitis was induced in C57BL/6 WT and uPAR KO
littermates. For dextran sodium sulfate (DSS)–induced colitis,
mice received 2.5% DSS in drinking water ad libitum for 5 days.
Body weights were recorded and referred as percent value of the
initial weight. To assess disease activity index (DAI), feces were
collected from each mouse of the experimental groups and eval-
uated for consistency and the presence of occult blood (Hemoc-
cult SENSA; Beckman Coulter, Indianapolis, IN).
The DAI was then calculated as average of 3 different
parameters: body weight loss (score 1: 1%–5%; score 2: 5%–10%;
score 3: 10%–15%; score 4: more than 15%), blood in the feces
(score 0: no blood; score 2: occult blood; score 4: visible blood), and
feces consistency (score 0: well formed; score 2: soft; score 4: diar-
rhea). At the end of treatment, mice were killed, colons were excised,
and colon length from the end of the cecum to the anus was recorded.
For 2,4,6-trinitrobenzene sulfonic acid (TNBS)–induced
colitis, mice were anesthetized and received an intrarectal injection
of 2.5 mg/mouse of TNBS in 15% ethanol or 15% ethanol alone as
a control. After instillation, mice were held in an upright position
for 3 minutes to avoid reﬂux. Weight loss was monitored daily. At
the end of treatment, mice were killed and colons were excised.
For both models, mice were divided into 3 experimental
groups. The ﬁrst group was treated with intraperitoneal injection
of [SRSRY] at 3 mg/kg every 2 days, starting from 2 days before
DSS administration or TNBS instillation. The control group
received the same amount of physiological solution, whereas the
third group was left untreated. Colons from colitic and healthy
mice were histologically evaluated using 4 mM parafﬁn sections
stained with hematoxylin and eosin. A pathologist blinded to
treatments and genotype of the tissue evaluated the degree of
inﬂammatory cell inﬁltration and mucosal damage.
In parallel experiments, colonic tissues were employed for
the isolation of lamina-propria (LP) mononuclear cells (LPMCs)
or immediately frozen on dry ice for protein extraction and
enzyme-linked immunosorbent assay (ELISA) analysis.
Characterization of Murine LPMCs
LPMCs were obtained from healthy and inﬂamed colonic
tissues, as previously described.6 Brieﬂy, colons were cut longitu-
dinally and washed in phosphate-buffered saline containing 1% fetal
bovine serum and 1 mM dithiothreitol for 15 minutes at 238C.
Enzymatic digestion was then performed in RPMI medium (Invi-
trogen) supplemented with 10% fetal bovine serum, 0.5 mg/mL
collagenase type VIII (Sigma-Aldrich), 20 mg/mL DNase I (Roche
Diagnostics, Milan, Italy), 100 U/mL penicillin, and 100 mg/mL
streptomycin for 60 minutes at 378C with gentle shaking. The cell
suspension obtained was passed through a 100-mm ﬁlter and clar-
iﬁed over 70-mm nylon mesh. The total amount of live cells was
determined by Trypan blue exclusion count on Neubauer chamber.
To characterize the different myeloid populations, we
stained murine LP cells with the following ﬂuorochrome-
conjugated antibodies: PerCP-conjugated anti-mouse CD45,
Paciﬁc Blue–conjugated anti-mouse CD11b, FITC-conjugated
anti-mouse Ly6C, APC-conjugated anti-mouse F4/80, and PE-
Cy7.7-conjugated anti-mouse CD11c (all from BD Biosciences-
Pharmingen, Mountain View, CA). Fluorochrome-conjugated,
isotype-matched control antibodies were included to assess back-
ground ﬂuorescence. All incubations were done in 3% bovine
serum albumin, supplemented with the corresponding immuno-
globulin G to minimize nonspeciﬁc binding.
ELISA
Proteins were extracted from colons of healthy and colitic
mice, as previously described.6 The presence of interleukin (IL)
1b, IL-6, IL-10, and tumor necrosis factor (TNF) a was quantiﬁed
by ELISA following the manufacturer’s instructions (Duo Set
ELISA; R&D systems) and normalized over the total amount of
proteins extracted.
Statistical Analyses
The results are expressed as mean 6 SD of the number of
indicated determinations. Data were analyzed by 1-way analysis
of variance and post hoc Bonferonni’s modiﬁed t test for multiple
comparisons. P , 0.05 was accepted as signiﬁcant.
RESULTS
The Peptide [SRSRY] Inhibits Agonist-
dependent FPR1 Activation in M1 Polarized
THP-1 Cells and Prevents M1 Polarization
PMA-differentiated THP-1 cells responded to LPS/IFNg,
resulting in M1 polarization, as expected. Indeed, PMA-
differentiated THP-1 macrophages showed a rounded and
spindle-shaped morphology, whereas M1 polarized macrophages
adopted a “dendritic”-like morphology with the appearance of large
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ﬁlopodia (Fig. 1A). Because chemokine repertoires of mononuclear
phagocytes exposed to polarizing stimuli are profoundly different,13
M1 polarization was ascertained by determining their cytokine pro-
ﬁle. Accordingly, M1 polarized cells secreted higher levels of
CXCL-10, CXCL-11, IL-1b, IL-6, and TNF-a as compared with
M0 and showed a signiﬁcant increase of CCL5 and CD54 (Fig.
1B), conﬁrming the M1 activation status of the macrophages.
We have previously shown that the peptide [SRSRY]
inhibits fMLF-directed migration of monocytes and macrophages
by interfering with both ligand uptake and internalization of
FPR1.12 According to Gemperle et al,17 we found that M1 polar-
ized macrophages express high levels of FPR1 on cell surface
(Fig. 1C). FPR1 is internalized in response to agonist stimulation,
this process being a prerequisite for receptor activation.18 Incuba-
tion of M1 macrophages with N-formyl-Nle-Leu-Phe-Nle-Tyr-
Lys-(fMLF)-ﬂuorescein resulted in the appearance of numerous
intracytoplasmic green ﬂuorescent spots (arrows), which disap-
peared in M1 macrophages preincubated with excess of nonﬂuo-
rescent fMLF, as expected. We found that, like fMLF, 100 nM
[SRSRY] prevented agonist-dependent FPR1 internalization,
whereas the scrambled control peptide [RSSYR] did not exert
such effect (Fig. 1D), indicating that [SRSRY] is able to inhibit
FPR1 activation also on polarized M1 macrophages.
It has been documented that LPS upregulates FPR1 mRNA
levels promoting both enhanced transcription and mRNA stabil-
ity19 and that LPS and fMLF regulate the induction of inﬂamma-
tion in a synergistic manner both in vitro and in vivo,20 raising the
possibility that [SRSRY] may interfere with LPS-induced signal-
ing. Therefore, we investigated the effects of [SRSRY] on M1
polarization. Interestingly, when PMA-differentiated THP-1 cells
were exposed to polarizing stimuli in the presence of 10 nM
[SRSRY], a general reduction of chemokine repertoires was
observed, whereas the control scramble peptide [RSSYR] did
not exert such effect (Fig. 1B). In particular, [SRSRY] dramati-
cally reduced secretion of CXCL-10, CXCL-11, IL-1b, IL-6, IL-
8, and TNF-a (Fig. 1B). These ﬁndings indicate that the peptide
[SRSRY] blocks agonist-dependent FPR1 internalization in M1
polarized macrophages and prevents M0 to M1 transition.
The Peptide [SRSRY] Inhibits M1 Polarized
Macrophage Migration Affecting
Cytoskeletal Reorganization
The mechanisms by which cells move when subjected to
a chemoattractant gradient involve changes in cytoskeletal
organization, which provide both the protrusive and contractile
forces necessary for cell migration. To analyze the effects of
FIGURE 1. The peptide [SRSRY] reduces cytokine levels secreted by FPR1 expressing M1 polarized macrophages. A, Representative images of PMA-
(M0) and INFg/LPS (M1)-stimulated THP-1 cells analyzed by phase contrast microscopy at ·200 (scale bar: 100 mm). B, Cytokine levels secreted by
PMA-differentiated THP-1 cells exposed to LPS/IFNg (M1), LPS/IFNg + 10 nM [SRSRY], or LPS/IFNg + 10 nM [RSSYR] for 48 hours, expressed as
percentage of cytokines secreted by M0 macrophages. The pixel density of each spot was measured using NIH Image J 2.0 software. The intensity
of positive control spots was used to normalize results between the membranes. Data were averaged over the duplicate spots. *P , 0.05, **P ,
0.01. C, Representative images of M1 polarized THP-1 cells double stained for FPR1 and 4-6-diamidino-2-phenylindole dye. Original magniﬁcation:
·400, scale bar: 10 mm. D, Representative images of M1 polarized THP-1 cells incubated with diluents (none), 100 nM fMLF, 100 nM [SRSRY], or 100
nM [RSSYR] for 30 minutes at 378C, exposed to 10 nM N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-ﬂuorescein for additional 30 minutes at 378C and then
visualized using a Zeiss 510 META LSM microscope. Arrows indicate the intracytoplasmic green ﬂuorescent spots. Scale bar: 10 mm. Original
magniﬁcations: ·630.
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[SRSRY] on the motility of M1 polarized macrophages, cells
grown adherent onto a glass slide were exposed to diluents, 10
nM fMLF gradient 6 10 nM [SRSRY] or 10 nM [RSSYR] in
a DUNN chamber for 6 hours, and then stained with rhodamine-
phalloidin. First, migrating cells, located on the ring separating the
inner and outer chambers, were analyzed for their cytoskeletal
organization (Fig. 2). In the absence of fMLF gradient (CTRL),
cells exhibited a ﬂattened morphology with multiple unpolarized
F-actin–rich protrusions. When subjected to the fMLF gradient
alone or mixed to the control peptide [RSSYR], M1 macro-
phages exhibited an elongated morphology and recognizable
aligned protrusions associated to locomotion in the 83% and
80% of cell population, respectively (Fig. 2A). Vice versa, the
addition of [SRSRY] peptide to the fMLF gradient reduced cell
elongation and alignment with the appearance of F-actin linear
distribution along the plasma membranes in the 63% of M1 cell
population (Fig. 2A). Next, to assess whether [SRSRY] affects
their motility, cells located on the ring were visualized by an
inverted microscope and counted. M1 macrophage exposure to
10 nM fMLF elicited a considerable cell migration (Fig. 2B, C),
reaching 294% of the basal cell migration, which was unchanged
by the presence of 10 nM [RSSYR]. On the contrary, the addi-
tion of 10 nM [SRSRY] to the outer chambers drastically
reduced M1 polarized macrophage migration below the basal
level (Fig. 2B, C). The inhibitory effect exerted by [SRSRY]
on cytoskeletal organization and migration of M1 macrophages
was not due to a reduced cell viability as the number of macro-
phages exposed to polarizing stimuli did not change in the pres-
ence of 10 mM [SRSRY] as assessed by a colorimetric method
for quantiﬁcation of viable cells (Fig. 2D). Together, these re-
sults indicated that the peptide [SRSRY] inhibits motility of M1
polarized macrophages.
In Vivo Administration of [SRSRY] Reduced
Colitis Susceptibility, Independent of
Endogenous uPAR Expression
Given the effects elicited by [SRSRY] in vitro and the
important role of macrophages in acute and chronic inﬂammation,
we investigated whether [SRSRY] might affect the development
of experimental colitis. To this end, colitis was initially induced
by the administration of DSS for 5 days, as described in the
Materials and Methods. Furthermore, mice were injected
FIGURE 2. The peptide [SRSRY] inhibits migration of M1 polarized macrophages causing a marked inhibition of cytoskeletal reorganization. M1
polarized THP-1 cells were allowed to migrate for 6 hours in a DUNN chamber toward diluents (CTRL), or a fMLF chemotactic gradient, in the
absence (none) or in the presence of 10 nM [SRSRY] or 10 nM [RSSYR]. A, Representative images of M1 polarized THP-1 cells located on the ring
separating the inner and outer chambers and stained with rhodamine-phalloidin. Scale bar: 5 mm. Original magniﬁcations: ·400. B, Representative
images of cells located on the ring separating the inner and outer of the DUNN chamber. Scale bar: 100 mm. Original magniﬁcations: ·50. C, For
quantitative analysis of cell migration, M1 polarized cells located on the ring were counted. The arbitrary value of 100% was given to the basal cell
migration, assessed in the absence of chemoattractant (CTRL: ——), and the results were expressed as percentage of the basal cell migration.
**P, 0.001. D, M1 polarized THP-1 cells were exposed to diluents (none), 10 mM [SRSRY] or 10 mM [RSSYR]. Medium with or without peptides was
replaced every 24 hours. At the indicated times, the absorbance of adherent cells stained with tetrazolium/formazan was assessed with
a Microplate Reader.
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intraperitoneally with 3 mg/kg [SRSRY] every 2 days, starting 2
days before the administration of DSS.
Interestingly, [SRSRY] treatment reduced body weight loss
(Fig. 3A), and overall, all the signs of acute intestinal inﬂamma-
tion, including anal bleeding and stool consistency, were signiﬁ-
cantly diminished in [SRSRY]-treated mice (DAI, Fig. 3B).
We have previously shown that [SRSRY] inhibitory
effects on monocyte locomotion are due to its ability to inhibit
FPR1 signaling.12 Thus, we assessed whether the endogenous
expression of uPAR is required to elicit the beneﬁcial effects
exerted by [SRSRY] administration. To this end, uPAR KO
littermates were subjected to DSS-induced colitis. uPAR KO
mice experienced a severe colitis compared with WT littermates,
as observed by body weight loss and DAI (Fig. 3C, D), conﬁrm-
ing our previous results.6 In keeping with the previously re-
ported ability of [SRSRY] to inhibit FPR1 activation,12 we
found that intraperitoneal administration of [SRSRY] signiﬁ-
cantly improved body weight loss and DAI, also in the absence
of uPAR expression (Fig. 3C, D). Indeed, both histological and
endoscopic analyses showed a reduced intestinal inﬂammation
not only in WT but also in uPAR KO treated mice, which dis-
played a lower number of edema and a decreased mucosal inﬁl-
trate as compared with untreated mice (Fig. 3E). Accordingly,
analyses of the colon length and histological and endoscopic
scores assessed at the end of the treatment indicate that beneﬁ-
cial effects exerted by intraperitoneal administration of
[SRSRY] does occur and are independent of endogenous uPAR
expression (Fig. 3F).
[SRSRY] Administration Reduces the Severity
of TNBS-induced Colitis
We next investigated whether [SRSRY] could reduce the
severity of TNBS model of experimental colitis, which induces
severe colonic inﬂammation resembling clinical and histopatho-
logical features of Crohn’s disease.21
Because we previously observed that the endogenous
expression of uPAR is not required to exert the protective effects
by [SRSRY] administration at least in the DSS-induced colitis
model, we compared the severity of TNBS-induced colitis in both
WT and uPAR KO littermates.
As expected, uPAR KO mice experienced a serious colonic
inﬂammation compared with WT littermates, as demonstrated by
body weight loss and histopathological signs of inﬂammation (Fig.
4). Interestingly, [SRSRY] administration was able to reduce the
severity of inﬂammation in both WT and uPAR KO littermates.
However, [SRSRY]-treated mice displayed a signiﬁcant reduction
of the body weight loss exclusively in the absence of endogenous
uPAR expression, whereas WT treated mice showed a similar trend
even if the differences were not signiﬁcant (Fig. 4A, B).
Furthermore, histopathological analysis conﬁrmed that
[SRSRY] administration was effective in reducing colonic inﬂam-
mation principally in uPAR KO mice, whereas WT mice showed
a slight improvement of the colon length and the histological
score (Fig. 4C, D).
Altogether, these results clearly indicate that [SRSRY] is
able to ameliorate in vivo the severity of experimental colitis.
[SRSRY] Modulates the Secretion of
Pro-inﬂammatory Cytokine During
Experimental Colitis
Because the DSS and TNBS models of colitis are
associated with an unbalanced cytokine proﬁle,21 we evaluated
whether [SRSRY] could affect the secretion of pro- and anti-
inﬂammatory cytokines.
To accomplish this goal, we quantiﬁed by ELISA the
amounts of IL-1b, IL-6, TNF-a, and IL-10 produced by colonic
tissues under steady-state conditions (before colitis induction) and
after intestinal injury. Comparable levels of cytokines were detected
in healthy mice, treated or not with [SRSRY] (data not shown). By
contrast, treatment with either DSS or TNBS induced a greater
increase of IL-1b, IL-6, and TNF-a, as expected21 (Fig. 5).
According to the ﬁnding that PMA-differentiated THP-1
cells exposed to polarizing stimuli in the presence of 10 nM
[SRSRY] secrete in vitro lower levels of IL-1b, IL-6, and TNF-
a as compared with untreated cells (Fig. 1B), we found that
[SRSRY] treatment signiﬁcantly reduced the release of IL-1b
(Fig. 5A), IL-6 (Fig. 5B), and TNF-a in colonic tissues (Fig.
5C). IL-10 has been prompted as a master regulator of intestinal
inﬂammation because it has been recognized as an immune mod-
ulatory cytokine that is capable of dampening T helper cells type
1-like responses.22 Intriguingly, [SRSRY] administration was able
to signiﬁcantly augment the mucosal levels of IL-10 after either
DSS administration or TNBS instillation (Fig. 5D).
Altogether these results clearly indicated that [SRSRY]
dampened intestinal inﬂammation. Furthermore, they also suggest
that other and more complex immune modulatory events affecting
Th1 responses and promoting IL-10 release may occur during
[SRSRY] administration.
[SRSRY] Reduces the Mucosal Inﬁltrate,
Decreasing the Recruitment of
Inﬂammatory Monocytes
We previously reported that [SRSRY] is a potent inhibitor
of monocyte transendothelial migration.12 Given the unbalanced
cytokine proﬁle observed, we reasoned that the beneﬁcial effect of
[SRSRY] administration might be due to an alteration of the
monocyte/macrophage inﬁltrate. Because uPAR plays an impor-
tant role in leukocyte recruitment after inﬂammation,4,23 to better
appreciate the effect of [SRSRY] treatment on monocyte/macro-
phage trafﬁcking, only uPAR KO mice were employed in this set
of experiments.
LPMCs were isolated from the healthy and inﬂamed colon of
uPAR KO mice, treated or not with [SRSRY]. We then
characterized myeloid cells (CD45+CD11b+) by the expression
of speciﬁc surface markers to distinguish between LP-dendritic
cells (F4/802CD11c+), LP-macrophages (F4/80+CD11c+/2Ly6C2),
LP-monocytes/macrophages (F4/80+CD11c+/2Ly6C+), and mono-
cytes (SSC-AlowF4/802CD11c2Ly6C+).
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FIGURE 3. In vivo administration of the peptide [SRSRY] reduces the severity of DSS-induced colitis. A, The severity of DSS-induced colitis was
assessed by monitoring body weight loss in WT mice, treated or not with [SRSRY]. B, The DAI was calculated as indicated in the Materials and
Methods. C and D, DSS-induced colitis was induced in uPAR KO mice and the severity assessed by body weight loss and DAI. E, Representative
images of the histological and endoscopic analyses, carried at the end of the experimental procedure in both WT and uPAR KO mice. F, Histogram
bars were plotted to represent colon length, histological score, and endoscopic score. Values were calculated as mean 6 SD of 3 independent
experiments. *P , 0.05, **P , 0.01.
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As expected, healthy mice possessed few leukocytes in the
uninﬂamed mucosa (CD45+ cells: 10.3% 6 2.5% over total vital
cells). Furthermore, myeloid cells (Fig. 6A) were mainly repre-
sented by residential macrophages (47.4% 6 2.5% over CD11b+
cells), whereas only a small amount of LP-monocytes/
macrophages (1.2% 6 1.5% over CD11b+ cells) and monocytes
were detected (7.2% 6 3.8% over CD11b+ cells).
In contrast, inﬂammation driven by DSS administration
induced a prominent recruitment of LP-leukocytes in the inﬂamed
mucosa, as expected (CD45+ cells: 40.1% 6 9.3% over total vital
cells). Furthermore, we noticed a signiﬁcant increase in the
relative percentage of both inﬂammatory monocytes (23.5% 6
8.5% over CD11b+ cells) and LP-monocytes/macrophages
(21.5% 6 5.5% over CD11b+ cells, Fig. 6B). Interestingly,
[SRSRY] treatment minimally affected the relative percentage
of LP-leukocytes (CD45+ cells: 38.3%6 6.5% over total vital cells).
Nevertheless, [SRSRY] was able to signiﬁcantly reduce the relative
amount of both inﬂammatory monocytes and LP-monocytes/
macrophages (Fig. 6B, D). Similar results were obtained in the
TNBS experimental model of colitis (Fig. 6C), even if a prevalent
recruitment of myeloid cells was evident, along with a huge incre-
ment of inﬂammatory monocytes and LP-monocytes/macrophages
FIGURE 4. [SRSRY] administration reduces the severity of the TNBS model of experimental colitis. A, C57BL/6 WT mice received intrarectal
administration of TNBS. Colitis severity was evaluated by recording body weight loss and compared with mice intrarectally injected with ethanol
(control) or with mice injected with [SRSRY]. B, TNBS-induced colitis was also induced in uPAR KO mice and the severity evaluated by body weight
recording. C, Representative images of the histological analysis, carried at the end of the experimental procedure in both TNBS-treated WT and
uPAR KO mice, injected with saline or [SRSRY]. Histogram bars were plotted to represent colon length and histological score. Values were cal-
culated as mean 6 SD of 3 independent experiments. *P , 0.05, **P , 0.01.
Genua et al Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2016
8 | www.ibdjournal.org
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
(69.5% 6 10.5% and 14.5% 6 3.5% over CD11b+ cells, respec-
tively). As for the DSS experimental model of colitis, [SRSRY] was
able to reduce the relative amount of inﬂammatory monocytes and
partially of LP-monocytes/macrophages (Fig. 6C, D).
Altogether these results clariﬁed that intraperitoneal injec-
tion of the peptide [SRSRY] is able to reduce intestinal
inﬂammation diminishing body weight loss and the DAI. These
beneﬁcial effects were due to an abridged recruitment of
inﬂammatory monocytes to the inﬂamed tissue.
DISCUSSION
Leukocyte migration across the blood barrier and into
tissues is one of the ﬁrst events during inﬂammation, immune
response against infection, and tissue remodeling and broadly
represents a key process in the pathogenesis of chronic inﬂam-
matory diseases. Although molecules that mediate leukocyte
motility have resulted in a signiﬁcant number of new targets that
hold promise for new therapies,24,25 we still need to reﬁne our
understanding on the molecules that are important for the trafﬁck-
ing of speciﬁc lymphocyte subsets in humans.
In this article, we propose the cyclized peptide [SRSRY] as
a new drug for treating chronic inﬂammatory diseases sustained
by increased motility of inﬂammatory monocytes and macro-
phages, such as IBD.
uPAR plays an important role in the regulation of leukocyte
trafﬁcking.26 The capability of uPAR to trigger cell migration
depends on its 88Ser-Arg-Ser-Arg-Tyr92 chemotactic sequence
that, even in the form of a synthetic linear peptide, promotes cell
migration by interacting with the G protein–coupled FPR1.9 We
have recently found that the cyclization of this sequence confers
stability to the peptide and reverts its function providing the abil-
ity to inhibit transendothelial migration of monocytes by blocking
fMLF-triggered FPR1 activation.12
FPR1 is recognized as a key molecule in sustaining
inﬂammatory environment.27 Activation of FPR1 results in
increased cell migration, phagocytosis, and release of pro-
inﬂammatory mediators, and the signaling cascade culminates in
heterologous desensitization of other receptors including chemo-
kine receptors CCR1, CCR5, and CXCR4.28–30 Thus, by interact-
ing with a variety of exogenous and host-derived agonists, FPR1
constitutes a novel pharmacological target.
During intestinal infection or inﬂammation, blood mono-
cytes accumulate in the LP and actively pursue invading micro-
organisms through uptake and degradation of the organism and
release of inﬂammatory mediators.31 In particular, M1 polarized
macrophages that are characterized by the secretion of high levels
of pro-inﬂammatory cytokines, high production of reactive nitro-
gen and oxygen intermediates, are implicated not only in initiating
but also in sustaining intestinal inﬂammation.32
In this study, we show that the peptide [SRSRY] inhibits
cytoskeletal reorganization and migration of M1 polarized macro-
phages toward an fMLF chemotactic gradient. Mechanistically, as
previously documented for monocytes and macrophages,12 the pep-
tide [SRSRY] blocks fMLF-dependent migration of M1 polarized
macrophages by interfering with both internalization and ligand
uptake of FPR1. When PMA-differentiated THP-1 cells were
exposed to polarizing stimuli (LPS/IFNg) in the presence of
[SRSRY], a general reduction of pro-inﬂammatory cytokine reper-
toire was observed, suggesting that [SRSRY] also interferes with
M0 to M1 transition. This ﬁnding is not surprising because LPS
and fMLF regulate both in vitro and in vivo the induction of
inﬂammation in a synergistic manner20 and FPR1 expression is
rapidly upregulated through both transcriptional and posttranscrip-
tional mechanisms in mouse macrophages in response to a wide
number of inﬂammatory stimuli, including LPS and TNF-a.19
FPR1 regulates macrophage activation through the activation of
nuclear factor kB (NF-kB), which in turn increases cytokine gene
transcription inducing the secretion of IL-1a, IL-1b, and IL-6 from
human peripheral blood mononuclear cells.29,33 Intriguingly, NF-kB
is a recognized mediator of LPS-triggered TLR4 signaling.33 Thus, it
FIGURE 5. [SRSRY] treatment reduces the severity of experimental
colitis through effect on the release of pro- and anti-inﬂammatory
cytokines. Colitis was induced in uPAR KO mice treated or not with
[SRSRY] by DSS or TNBS administration, as described in the Materials
and Methods. A, The levels of IL-1b in the mucosal protein extracts
obtained from inﬂamed colonic tissues were quantiﬁed by ELISA
assay. B–D, Similarly, the levels of IL-6, TNF-a, and IL-10 were assessed
after colitis induction in mucosal protein extracts. Histogram bars
represented the mean 6 SD of 3 independent experiments. *P, 0.05,
**P , 0.01.
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is difﬁcult to pinpoint the exact sequence of events and the contri-
bution of each subset of mediators in the inhibitory effects exerted
by [SRSRY]. It is conceivable to hypothesize that [SRSRY] inhib-
itory effect is mediated by FPR1 that, in turn, regulates macrophage
activation by modulating directly or indirectly multiple signaling
pathways. Moreover, THP-1 macrophages express high level of
uPAR, which interacts with the FPR1 through its uPAR88–92
sequence.8,9,11 Thus, in vitro, inhibitory effect exerted by [SRSRY]
on M1 polarization may be due to the inhibition of uPAR88–92-
dependent FPR1 activation. In vivo, N-formyl peptides derived
from bacterial and mitochondrial sources have been detected in
intestinal mucosa from patients with IBD and have been suggested
to support the development and progression of IBD.34 Probably,
during DSS- or TNBS-induced colitis in WT or uPAR KO mice,
[SRSRY] blocks both uPAR88–92- and fMLF-dependent FPR1 acti-
vation. The exact mechanism by which [SRSRY] counteracts M0 to
M1 transition will be the subject of a future research.
When administered in mice in which colitis had been
induced by DSS or TNBS, [SRSRY] exerts beneﬁcial effects,
most likely attenuating the recruitment of inﬂammatory monocytes
to the inﬂamed tissue. [SRSRY]-treated mice displayed a reduced
body weight loss and DAI. In agreement with its anti-inﬂammatory
property, [SRSRY] administration during DSS- or TNBS-induced
colitis caused a strong reduction of the cytokines IL-1b, IL-6, and
TNF-a and a statistically signiﬁcant increase of IL-10, which is
recognized as a master regulator of intestinal inﬂammation in virtue
of its ability to dampen Th1-like responses.22
Formyl peptides, which are released in the intestinal
microenvironment by all bacteria, and other ligands, such as sex
pheromones from Enterococcus faecalis and Enterococcus faeci-
um, promote directional migration of monocytes, neutrophils, and
other leukocytes by binding to FPR1.35 We cannot exclude that
neutrophils and other subset of leukocytes expressing FPR1 may
concur to the beneﬁcial effects exerted by [SRSRY] on
FIGURE 6. The recruitment of inﬂammatory monocytes is signiﬁcantly affected by [SRSRY] treatment during experimental colitis. Colitis was
induced in uPAR KO mice treated or not with [SRSRY] by DSS or TNBS administration, as described in the Materials and Methods. A, LPMCs were
initially evaluated in steady-state conditions by ﬂow cytometry analysis. Representative dot plots are showing the gating strategy used to identify
among CD45+CD11b+ myeloid cells: LP-dendritic cells (CD11c+F4/802), LP-macrophages (CD11c+/2Ly6C2F4/80+), LP-mono-macrophages
(CD11c+/2Ly6C+F4/80+), and inﬂammatory monocytes (SSCAlowCD11c2F4/802Ly6C+). B, LPMCs were assessed after DSS-induced colitis both in
saline-treated and [SRSRY]-treated mice. Representative dot plot showed a reduction both in LP-mono-macrophages and inﬂammatory mono-
cytes, whereas LP-macrophages slightly increased after [SRSRY] treatment. C, Representative dot plot of ﬂow cytometry analysis conducted in
TNBS-treated uPAR KO mice, comparing saline versus [SRSRY]-treated mice. [SRSRY] treatment affected the massive recruitment of both LP-mono-
macrophages and inﬂammatory monocytes. D, The absolute cell number of the population analyzed was calculated over the total number of live
cells. Histogram bars represented the mean6 SD of 3 independent experiments. The percent values in the dot plot are calculated among the total
number of CD45+ leukocytes. *P , 0.05, **P , 0.01.
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experimental colitis. Furthermore, because it is documented that
beside FPR1 also the related FPR2 is involved in leukocyte
recruitment for sustaining inﬂammatory environment19 and that
the 88Ser-Arg-Ser-Arg-Tyr92 chemotactic sequence of uPAR is
also able to bind FPR2,8 it will be interesting to explore the
possibility that FPR2 activity is also inhibited by [SRSRY].
We had previously shown that uPAR expression is
signiﬁcantly augmented on intestinal macrophages during exper-
imental colitis. This physiological response is required to dampen
intestinal inﬂammation because the absence of uPAR leads to an
increased production of inﬂammatory cytokines by macrophages
that showed an impaired phagocytosis and M1 polarization.6
Our data conﬁrmed the involvement of uPAR in controlling
macrophage polarization and underlined the important role of its
88Ser-Arg-Ser-Arg-Tyr92 sequence in the uPAR/FPR1 interaction.
Furthermore, we provide novel evidence regarding the in vivo
activity harbored by the cyclization of the peptide. Indeed,
[SRSRY] ameliorates the severity of experimental colitis, with
a pronounced effect in the absence of endogenous uPAR expres-
sion. In this context, [SRSRY] could restore the balance between
M0 and M1 polarized macrophages, thus reducing the severity of
colonic inﬂammation. Moreover, it is reasonable to expect that
[SRSRY] easily accesses to FPR1 avoiding competition with
endogenous uPAR. The effects elicited become even more appre-
ciable and likely revert the uPAR KO phenotype to the WT
condition.
Furthermore, although FPR1 expression has been found on
intestinal epithelial cell surface to promote intestinal epithelial
repair by inducing phosphatidylinositol 3-kinase–dependent Rac1
and Cdc42 activation,36 it is well established that during inﬂam-
mation FPR1 expression is strongly and rapidly upregulated in
mouse macrophages and neutrophils,19 acting as a potent enhancer
of the inﬂammatory responses. However, the speciﬁc effect of
[SRSRY] on tissue repair remains to be investigated.
Given the ﬁnding that peptide [SRSRY] is able to
ameliorate in vivo the severity of experimental colitis, it may be
considered as a new FPR1 inhibitor that may be useful for the
generation of new pharmacological treatments for chronic inﬂam-
matory diseases.
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